<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Single-agent cetuximab is safe and active in elderly patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>A cetuximab-<z:chebi fb="0" ids="31348">capecitabine</z:chebi> combination has not previously been tested in elderly patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIAL AND METHODS: Sixty-six patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were treated with cetuximab as a 400 mg/m2 i.v. infusion followed by 250 mg/m2 i.v. weekly plus <z:chebi fb="0" ids="31348">capecitabine</z:chebi> at a dose of 1,250 mg/m2 every 12 hours </plain></SENT>
<SENT sid="3" pm="."><plain>After the inclusion of 27 patients, the protocol was amended for safety reasons, reducing the dose of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> to 1,000 mg/m2 every 12 hours </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-nine additional patients were treated with the reduced dose of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The overall response rate was 31.8% </plain></SENT>
<SENT sid="6" pm="."><plain>KRAS status was determined in 58 patients (88%) </plain></SENT>
<SENT sid="7" pm="."><plain>Fourteen of 29 patients with <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> responded (48.3%; 95% confidence interval [CI], 29.4%-67.5%), compared with six of 29 patients with mutant KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (20.7%; 95% CI, 8.0%-39.7%) </plain></SENT>
<SENT sid="8" pm="."><plain>The median progression-free survival (PFS) interval was 7.1 months </plain></SENT>
<SENT sid="9" pm="."><plain>The median PFS interval for patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS was significantly longer than for those with mutant KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (8.4 months versus 6.0 months; p = .024) </plain></SENT>
<SENT sid="10" pm="."><plain>The high incidence of severe <z:hpo ids='HP_0001818'>paronychia</z:hpo> (29.6%) declined (7.7%) after <z:chebi fb="0" ids="31348">capecitabine</z:chebi> dose adjustment </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Cetuximab plus <z:chebi fb="0" ids="31348">capecitabine</z:chebi> at a dose of 1,000 mg/m2 every 12 hours may be an alternative to more aggressive regimens in elderly patients with advanced <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>